Bing

SEARCH HISTORY

NEW YORK (TheStreet) -- Shares of BioMarin Pharmaceutical (BMRN - Get Report) were gaining 0.2% to $138.17 on light trading volume on Monday afternoon. On Wednesday, analyst firm SunTrust Robinson …
The Street · 6/22/2015
BioMarin (BMRN) stock surged on Thursday, jumping as much as 12% after the biotech company reported promising Phase II trial data for a drug treating dwarfism. The stock’s surge is also lifting shares of the …
Investor Place · 6/18/2015
IBB
BioMarin Pharmaceutical (NASDAQ:BMRN)‘s stock had its “hold” rating reaffirmed by equities researchers at Robert W. Baird in a research report issued on Monday, AnalystRatingsNetwork.com reports. BMRN has been the subject of a number of …
Ticker Report · 6/29/2015
More from Bing News
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) BMRN has been positive in eight of the past 10 third quarters, averaging a three-month gain of 14.4%. Moreover, the stock is a long-term outperformer, soaring 50% year-to-date to trade at $135.74, and more …
Schaeffer's Investment Research · 3 hours ago
Just a few days after the EMA accepted BioMarin’s BMRN regulatory application for its experimental ... declined 3.7% over the last five trading days (See the last biotech stock roundup here: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine ...
Yahoo Finance · 16 hours ago
Immunotherapy Deal
BioMarin Pharmaceutical (NASDAQ:BMRN)‘s stock had its “neutral” rating reiterated by Wedbush in a research note issued on Friday. They currently have a $130.00 target price on the stock. Wedbush’s price target points to a potential downside of …
sleekmoney.com · 6/20/2015
Lumenis Ltd (LMNS) traded at $13.75 + 1.67 (13.82 pct) on 2,455,557 total stock volume. The company is +47.22 pct year-to-date, and +49.24 pct during the last 12 months. BioMarin Pharmaceutical Inc. (BMRN) …
Fx Pips · 6/19/2015
BioMarin Pharmaceutical (NASDAQ:BMRN) is one of today's notable stocks on the rise, up 1.7% to $134.62. The Dow is trading fractionally higher to 17,630 and the S&P is currently up 0.2% to 2,062. BioMarin Pharmaceutical Inc. develops and …
Financial News Network Online · ByRobert Cotter · 6/30/2015
BioMarin Pharmaceutical
Robert W. Baird reaffirmed their hold rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note issued to investors on Monday, Marketbeat reports. The firm currently has a $133.00 price target on the stock. In other BioMarin ...
wkrb13.com · 1 day ago
Baird transferred coverage and downgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Outperform to Neutral with a ... we do not see an attractive risk-reward on the stock here and believe the Prosensa acquisition and recent pipeline updates are ...
StreetInsider · 6/19/2015